Ersin Çagrı Simsek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ersin Çagrı Simsek has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Begum Ozdengulsun
Primary Care Medical Team, Pfizer Türkiye, 34394 İstanbul, Türkiye
1 shared publication - Dursun Aras
Department of Cardiology, Medipol University Hospital, 34196 İstanbul, Türkiye
1 shared publication - Emine Dundar Ahi
Primary Care Medical Team, Pfizer Türkiye, 34394 İstanbul, Türkiye
1 shared publication - Murat Gücün
Nephrology Clinic, Koşuyolu High Specialization Education and Research Hospital, 34865 İstanbul, Türkiye
1 shared publication - Seher Tanrikulu
Department of Endocrinology, Acibadem Atasehir Hospital, Istanbul, Turkey
1 shared publication - Sena Sert
Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 26 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1758
Additional Stroke Risk Factors Beyond the CHA2DS2-VA Score in Non-Valvular Atrial Fibrillation: An Interdisciplinary Expert Opinion
Background/Objectives: Comorbidity and risk factor management and avoiding stroke are pillars of optimal atrial fibrillation management. In this article, the latest literature on additional stroke risk factors not included in the CHA2DS2-VA score is reviewed in patients with non-valvular atrial fibrillation (NVAF). The possible clinical impacts of the additional risk factors in NVAF patients with a CHA2DS2-VA score of 1 are compiled with insights in an interdisciplinary panel discussion to refine daily clinical practice. Methods: The panel was composed of three cardiologists, one endocrinologist, and a nephrologist. The panel members finalized twenty open-ended questions covering major problems in stroke risk stratification in NVAF patients with a score of 1. The shortcomings of this clinical-based model for stroke prevention and its possible outcomes were discussed with evidence-based recommendations. The meeting outcomes are addressed for daily clinical adaptation in the present article. Results: Recent evidence suggests that the CHA2DS2-VA score may have shortcomings in a striking rate of NVAF patients with a score of 1. The growing body of evidence suggests that combining clinical, laboratory, and imaging predictors with the CHA2DS2-VA score may further refine stroke risk prediction and aid in decision-making for anticoagulation of NVAF patients with a score of 1. Conclusions: The interdisciplinary expert panel offered several recommendations based on the assessment of additional risk factors, which may enable clinicians to identify individualized patient characteristics and early multidisciplinary prevention of disease progression and personalized improvements in the long-term cardiovascular outcomes in NVAF patients with a CHA2DS2-VA score of 1.
- 26 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1758
Open AccessAdditional Stroke Risk Factors Beyond the CHA2DS2-VA Score in Non-Valvular Atrial Fibrillation: An Interdisciplinary Expert Opinion
Background/Objectives: Comorbidity and risk factor management and avoiding stroke are pillars of optimal atrial fibrillation management. In this article, the latest literature on additional stroke risk factors not included in the CHA2DS2-VA score is reviewed in patients with non-valvular atrial fibrillation (NVAF). The possible clinical impacts of the additional risk factors in NVAF patients with a CHA2DS2-VA score of 1 are compiled with insights in an interdisciplinary panel discussion to refine daily clinical practice. Methods: The panel was composed of three cardiologists, one endocrinologist, and a nephrologist. The panel members finalized twenty open-ended questions covering major problems in stroke risk stratification in NVAF patients with a score of 1. The shortcomings of this clinical-based model for stroke prevention and its possible outcomes were discussed with evidence-based recommendations. The meeting outcomes are addressed for daily clinical adaptation in the present article. Results: Recent evidence suggests that the CHA2DS2-VA score may have shortcomings in a striking rate of NVAF patients with a score of 1. The growing body of evidence suggests that combining clinical, laboratory, and imaging predictors with the CHA2DS2-VA score may further refine stroke risk prediction and aid in decision-making for anticoagulation of NVAF patients with a score of 1. Conclusions: The interdisciplinary expert panel offered several recommendations based on the assessment of additional risk factors, which may enable clinicians to identify individualized patient characteristics and early multidisciplinary prevention of disease progression and personalized improvements in the long-term cardiovascular outcomes in NVAF patients with a CHA2DS2-VA score of 1.